Health
New weight-loss shot shows major fat reduction, but experts urge caution
NEWYou can now listen to Fox News articles!
An experimental medication was shown to help boost weight loss by up to 20%, a study found.
Eloralintide, a once-weekly injectable manufactured by Eli Lilly in Indianapolis, led to “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes, according to a press release.
The drug was generally well-tolerated by the study participants.
An experimental medication was shown to help boost weight loss by up to 20%, a study found. (iStock)
The Phase 2 trial, which was funded by Eli Lilly, included 263 adults. After 48 weeks, they had lost between 9.5% and 20.1% of their body weight, compared to 0.4% for those taking the placebo.
Treatment with eloralintide was also linked to improvements in waist circumference, blood pressure, lipid profiles, glycemic control and markers of inflammation, all of which can increase cardiometabolic risk, according to the researchers.
WEIGHT LOSS DRUGS COULD ADD YEARS TO AMERICANS’ LIVES, RESEARCHERS PROJECT
“The weight loss we saw in the study is clinically impactful,” lead study author Liana K. Billings, M.D., director of clinical and genetics research in diabetes and cardiometabolic disease at Endeavor Health in Skokie, Illinois, said in the press release.
“With this degree of weight loss in only 48 weeks, we see people having improvement or resolution in other conditions like hypertension, hyperlipidemia, osteoarthritis, sleep apnea and more weight-related conditions.”
Eloralintide, a once-weekly injectable manufactured by Eli Lilly in Indianapolis, led to “meaningful, dose-dependent weight loss” in adults who were overweight or obese but did not have diabetes. (Getty Images)
“Furthermore, in the study, we did not see a nadir or plateau of weight loss, so I would expect weight loss to continue if the study continued for a longer duration. Additionally, up to 90% of participants on eloralintide improved by at least one BMI category,” she added.
The results were published in The Lancet and presented at ObesityWeek 2025 in Atlanta, Georgia, earlier this month.
AMERICA’S FATTEST STATES REVEALED — AND HOW OZEMPIC IS CHANGING THE MAP
While popular GLP-1 drugs — including Ozempic, Wegovy, Mounjaro and Zepbound — work by mimicking the gut hormone GLP-1 (glucagon-like peptide-1), eloralintide is a selective amylin receptor agonist that works by mimicking a pancreas hormone called amylin.
Similar to GLP-1s, it helps to slow digestion, reduce appetite and control blood sugar after meals. It has not yet been FDA-approved for clinical use.
While GLP-1 drugs work by mimicking the gut hormone GLP-1, eloralintide is a selective amylin receptor agonist that works by mimicking a pancreas hormone called amylin. (iStock)
The biggest side effects noted for eloralintide were mild to moderate gastrointestinal symptoms and fatigue, the researchers noted. These effects were greater at higher doses.
“Obesity is a complex condition, and no single treatment works for everyone,” said Billings.
“To truly address each patient’s needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them.”
COULD GLP-1 WEIGHT-LOSS MEDICATIONS LIKE OZEMPIC BECOME THE ‘EVERYTHING DRUG’?
Based on the trial results, the reseachers plan to launch Phase 3 clinical studies for obesity treatment by the end of this year, the president of Lilly Cardiometabolic Health confirmed to Fox News Digital. The drug is also being evaluated for use in combination with GLP-1 medications.
Dr. Brett Osborn, a Florida neurosurgeon and longevity expert, shared some concerns about the new anti-obesity agents being developed.
“Bottom line: If an individual has an experienced and competent physician supervising their care — and driving the formation of healthy habits in addition to simply using the medication — they will lose weight,” a doctor said. (iStock)
“Between all the agents out there, there is no way any person cannot lose weight when coupled with progressive resistance training and attention to their daily macronutrient intake, even if only a little,” the doctor, who was not involved in the study, told Fox News Digital.
“Yet big pharma will continue to search for novel targets to introduce a new drug that will likely prove similarly, yet not more, efficacious than the current agents. There are enough agents out there to drive weight loss to a malnutrition status.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Osborn also noted that the lower cardiovascular risk associated with the drug was likely due to the participants losing body fat, which reduces the risk for all age-related diseases.
“Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term.”
“Bottom line: If an individual has an experienced and competent physician supervising their care — and driving the formation of healthy habits in addition to simply using the medication — they will lose weight,” he said.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Sue Decotiis, M.D., a medical weight-loss doctor in New York City, also shared her thoughts on eloralintide’s potential as an alternative treatment.
“It seems that the more receptor systems that are influenced, the more weight a patient can lose,” she told Fox News Digital. “This is why tirzepatide (Mounjaro, Zepbound), which hits two receptors, induced more weight loss than Ozempic and Wegovy.”
“To truly address each patient’s needs, we need therapies with different mechanisms of action so that each person can receive the treatment that offers the best balance of effectiveness and tolerability for them,” a researcher said. (iStock)
“In my practice, I witnessed significantly better results with tirzepatide when patients were switched from Ozempic.”
Hitting more receptors may be the answer for those patients who do not respond well or who “hit the wall” with simpler drugs, according to Decotiis, who also was not involved in the study.
“For long-term safety and results, peptide drugs show promise,” she said.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Whitney Di Bona, in-house attorney and consumer safety advocate for Drugwatch, noted that while the Phase 2 results are “promising,” it is important to be cautious.
“These drugs have been used for years, but new safety concerns keep appearing,” the Florida-based expert told Fox News Digital. Some of those include a potentially serious eye condition, delayed stomach emptying, bowel obstruction and serious digestive problems, which have led to many lawsuits.
CLICK HERE FOR MORE HEALTH STORIES
“Some side effects are rare or take time to show up, so it is important to monitor new drugs like eloralintide for safety over the long term,” Di Bona advised. “Even with careful studies, some risks may only become clear after the drug is used by many people.”
Health
Dementia risk signals could lie in simple blood pressure readings, researchers say
NEWYou can now listen to Fox News articles!
Simple measurements taken during routine blood pressure checks could predict dementia risk years before symptoms appear.
That’s according to new research presented this week at the American College of Cardiology’s Annual Scientific Session in Louisiana.
The findings draw on two studies led by researchers at Georgetown University, which suggest that monitoring how blood vessels age and stiffen over time can provide a window into future cognitive health.
LURKING DEMENTIA RISK EXPOSED BY BREAKTHROUGH TEST 25 YEARS BEFORE SYMPTOMS
Data shows rates of dementia and aging-related cognitive decline are expected to increase as populations age, and half of U.S. adults have high blood pressure (hypertension).
Scientists believe that efforts to better address hypertension, a key contributor to heart disease and a risk factor for dementia, could affect both cardiac and brain health.
Data shows rates of dementia and aging-related cognitive decline are expected to increase as populations age. Meanwhile, half of U.S. adults have high blood pressure. (iStock)
“Blood pressure management isn’t just about preventing heart attacks and strokes; it may also be one of the most actionable strategies for preserving cognitive health,” Dr. Newton Nyirenda, the study’s lead author and an epidemiologist at Georgetown University in Washington, said in a press release.
The research focused on two metrics, the pulse pressure-heart rate index and estimated pulse wave velocity. Both were calculated using data collected during standard doctor visits, such as heart rate, age and blood pressure.
“Blood pressure management isn’t just about preventing heart attacks and strokes; it may also be one of the most actionable strategies for preserving cognitive health.”
Researchers examined five years of data patterns for more than 8,500 people in the SPRINT trial, a large study of adults 50 years and older with hypertension. In the follow-up, 323 of the participants developed probable dementia.
HIDDEN BRAIN CONDITION MAY QUADRUPLE DEMENTIA RISK IN OLDER ADULTS, STUDY SUGGESTS
In one study, the team found the pulse pressure-heart rate index was a strong independent predictor of dementia risk in adults over 50. For participants under 65, every one-unit increase was associated with a 76% higher risk of developing dementia.
For participants under 65, an increase in the pulse pressure-heart rate index was associated with a 76% higher risk of developing dementia. (iStock)
The second study found that adults with consistently elevated or rapidly increasing pulse wave velocity were more likely to develop dementia than those with stable velocity, even after accounting for factors like smoking, gender and cardiovascular history.
CLICK HERE FOR MORE HEALTH STORIES
“Our findings suggest that vascular aging patterns may provide meaningful insight into future dementia risk,” said Nyirenda. “This reinforces the idea that managing vascular health earlier in life may influence long-term brain health.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The team emphasized that clinicians should tailor risk assessments and treatment strategies to the individual.
Further studies are needed to confirm these parameters and determine whether changing vascular aging trajectories reduces dementia risk. (iStock)
“You don’t want to wait until a patient starts manifesting cognitive decline before you act,” said senior study author Sula Mazimba, an associate professor at the University of Virginia.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Researchers noted the study could not establish causation. Other limitations included the fact that participants already had hypertension and elevated cardiovascular risk, meaning the findings may not apply to people without those conditions.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Further studies are needed to confirm these findings and to determine whether improving blood vessel health over time could reduce dementia risk.
Health
Everything You Need To Know About Zepbound for Weight Loss, Including Costs
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Health
‘Gas station heroin’ banned in another state amid nationwide crackdowns
NEWYou can now listen to Fox News articles!
A dangerous substance dubbed “gas station heroin” continues to alarm medical professionals, with more states making moves to restrict or ban tianeptine.
Fourteen states have officially classified the tricyclic antidepressant as a Schedule I controlled substance.
Connecticut is the latest state to crack down, officially banning the sale and use of the substance starting on Wednesday.
HEALTH OFFICIALS WARN OF DANGEROUS SUBSTANCE AVAILABLE IN STORES ACROSS THE NATION
Tianeptine, which can produce euphoria in higher doses, can be more potent than morphine and addictive opioids, according to the U.S. Food and Drug Administration.
Some countries have taken steps to restrict how tianeptine is prescribed or dispensed, and have even revised the labels to warn people of its potential addictive qualities.
Tianeptine can be more potent than morphine and addictive opioids. (iStock)
Misuse of tianeptine can cause severe adverse health effects, including respiratory depression, severe sedation and death, according to the Drug Enforcement Administration.
Some companies market the drug as an aid for pain, anxiety and depression, or as a means of improving mental alertness in a pill, powder, salt or liquid form.
The products are typically sold at convenience stores, gas stations, vape shops and online retailers, and go by names like Tianaa, ZaZa, Neptune’s Fix, Pegasus and TD Red.
Connecticut is the 15th state to classify tianeptine as a Schedule I controlled substance. (Markus Scholz/picture alliance via Getty Images)
Connecticut Lt. Gov. Susan Bysiewicz said in a press release that the schedule change is a necessary step to combat addiction.
“With false marketing that led consumers to believe these are safe products, and with candy-like flavor options, these substances posed a clear threat to those battling substance-use disorder and our youngest residents,” she added.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The Nutmeg State also added Mitragyna speciosa (kratom), 7-hydroxymitragynine, Bromazolam, Flubromazolam, Nitazenes and Phenibut to the schedule classification.
Earlier this month, FDA Commissioner Martin Makary penned a letter sounding the alarm on what he called a “dangerous and growing health trend.”
CLICK HERE FOR MORE LIFESTYLE STORIES
“I am very concerned,” Makary wrote. “I want the public to be especially aware of this dangerous product and the serious and continuing risk it poses to America’s youth.”
New York-based Robert Schwaner, M.D., vice chair of system clinical affairs at Stony Brook Emergency Medicine, told Fox News Digital that the FDA has never approved tianeptine as a dietary supplement.
“As with heroin and other opioids, significant mu-opioid receptor stimulation ultimately results in a loss of respiratory drive and subsequent cardiac arrest.” (Dekalb County Sheriff’s Office)
“The euphoria at low doses is primarily due to increased serotonergic activity from its serotonin reuptake effects. With increasing doses, the mu-opioid receptor stimulation may become lethal,” said Schwaner. “As with heroin and other opioids, significant mu-opioid receptor stimulation ultimately results in a loss of respiratory drive and subsequent cardiac arrest.”
Schwaner said he believes the substance requires national regulation due to its addictive qualities.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“Acting at the same receptor as opioids, tianeptine has the potential for an individual to develop tolerance, subsequent dependence and withdrawal from its use,” he cautioned.
Fox News Digital reached out to the FDA for comment.
Fox News Digital’s Greg Wehner and Melissa Rudy contributed to this report.
-
Detroit, MI1 week agoDrummer Brian Pastoria, longtime Detroit music advocate, dies at 68
-
Science1 week agoHow a Melting Glacier in Antarctica Could Affect Tens of Millions Around the Globe
-
Movie Reviews1 week ago‘Youth’ Twitter review: Ken Karunaas impresses audiences; Suraj Venjaramoodu adds charm; music wins praise | – The Times of India
-
Sports6 days agoIOC addresses execution of 19-year-old Iranian wrestler Saleh Mohammadi
-
New Mexico5 days agoClovis shooting leaves one dead, four injured
-
Business1 week agoDisney’s new CEO says his focus is on storytelling and creativity
-
Technology5 days agoYouTube job scam text: How to spot it fast
-
Tennessee4 days agoTennessee Police Investigating Alleged Assault Involving ‘Reacher’ Star Alan Ritchson